Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2696940 | 0.94 | OPRM1 (0.42) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL2189905 | 0.85 | ALDH1A1 (0.36) | OPRM1OPRL1ALDH1A1POLBL3MBTL1 | |
| SCHEMBL1352136 | 0.85 | CCR2 (0.43) | OPRM1OPRD1OPRK1MAPTALDH1A1 | |
| SCHEMBL30901672 | 0.84 | KCNN4 (0.34) | OPRM1OPRL1OPRD1OPRK1GAA | |
| SCHEMBL1538752 | 0.84 | GAA (0.35) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL2699594 | 0.84 | OPRM1 (0.34) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL1559660 | 0.82 | OPRM1 (0.33) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL1606691 | 0.82 | OPRM1 (0.33) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL1606689 | 0.82 | OPRM1 (0.33) | OPRM1OPRL1OPRD1OPRK1MAPK1 | |
| SCHEMBL14915861 | 0.82 | OPRM1 (0.33) | OPRM1OPRL1OPRD1OPRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122748-B1 | PROCESS OF PREPARING 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)PYRIDIN-2-AMINE | ARQULE INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-20150266876-A1 | PROCESS OF PREPARING 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)PYRIDIN-2-AMINE | ARQULE, INC. | 2015-09-24 | — | — | US | claimed |
| US-9604989-B2 | Imidazopyridazines as Akt kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-20150266876-A1 | PROCESS OF PREPARING 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)PYRIDIN-2-AMINE | ARQULE, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2013-10-31 | — | — | US | disclosed |
| US-8288407-B2 | Substituted naphthyridine compounds as inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7576209-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080161317-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161317-A1 | Inhibitors of Akt activity | PIK3CD, PIK3CA, PIK3CG | OPRM1 4732/4885OPRL1 4397/4885OPRD1 3774/4885 |
| US-20150266876-A1 | PROCESS OF PREPARING 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)PYRIDIN-2-AMINE | PIR, PAH, PNMT | OPRM1 1386/4885OPRL1 2645/4885OPRD1 1644/4885 |
| US-20150368250-A1 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS | PI4KA, PI4KB, PIK3CD | OPRM1 4180/4885OPRL1 4469/4885OPRD1 3294/4885 |
| US-20110160183-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | OPRM1 4732/4885OPRL1 4397/4885OPRD1 3774/4885 |
| US-20130287763-A1 | COMBINATION THERAPY FOR TREATING CANCER COMPRISING AN IGF-1R INHIBITOR AND AN AKT INHIBITOR | IGF1R, IGFBP1, IGFBP2 | OPRM1 4278/4885OPRL1 2660/4885OPRD1 4321/4885 |
| US-20090253734-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | OPRM1 4732/4885OPRL1 4397/4885OPRD1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.